Genomics BioSci & Tech. Co.,Ltd. (TPE:4195)
Taiwan · Delayed Price · Currency is TWD 13.60
-0.60 (-4.23%)
At close: Sep 11, 2026
Genomics BioSci & Tech. Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 718.16 | 708.38 | 517.58 | 396.14 | 419 | 389.97 | |
Revenue Growth | 20.11% | 36.86% | 30.65% | -5.46% | 7.45% | -12.01% |
Cost of Revenue | 515.51 | 477.02 | 360.4 | 276.23 | 282.99 | 280.04 |
Gross Profit | 202.65 | 231.36 | 157.18 | 119.91 | 136.01 | 109.92 |
Selling, General & Admin | 239.55 | 223.48 | 207.53 | 148.47 | 131.79 | 121.69 |
Research & Development | 84.77 | 82.5 | 88.5 | 56.43 | 35.88 | 17.47 |
Operating Expenses | 332.17 | 315.52 | 297.47 | 201.81 | 169.53 | 138.58 |
Operating Income | -129.52 | -84.16 | -140.29 | -81.9 | -33.52 | -28.66 |
Interest Expense | -14.83 | -13.7 | -7.74 | -4.74 | -1.98 | -1.67 |
Interest & Investment Income | 1.87 | 2.11 | 2.37 | 2.09 | 0.35 | 0.27 |
Earnings From Equity Investments | - | - | -52.72 | -19.56 | -18.88 | -13.46 |
Currency Exchange Gain (Loss) | -1.65 | 1.19 | 0.43 | 0.86 | 0.72 | -1.31 |
Other Non Operating Income (Expenses) | -0.86 | -1.12 | 12.08 | 0.58 | 0.8 | 1.05 |
EBT Excluding Unusual Items | -144.99 | -95.68 | -185.87 | -102.67 | -52.5 | -43.78 |
Gain (Loss) on Sale of Investments | 89.33 | 25.14 | -47.06 | -65.29 | 124.76 | -9.31 |
Gain (Loss) on Sale of Assets | 0.08 | 2.89 | -1.06 | - | - | 65.18 |
Asset Writedown | - | - | -1.36 | - | - | - |
Other Unusual Items | 0.01 | 0.02 | 0 | 0.02 | - | 0.01 |
Pretax Income | -55.57 | -67.63 | -235.35 | -167.94 | 72.26 | 12.09 |
Income Tax Expense | 0.61 | - | - | 0.13 | 0.66 | - |
Earnings From Continuing Operations | -56.19 | -67.63 | -235.35 | -168.07 | 71.6 | 12.09 |
Net Income to Company | -56.19 | -67.63 | -235.35 | -168.07 | 71.6 | 12.09 |
Minority Interest in Earnings | 30.49 | 28.2 | 12.25 | - | - | 6.65 |
Net Income | -25.7 | -39.43 | -223.1 | -168.07 | 71.6 | 18.74 |
Net Income to Common | -25.7 | -39.43 | -223.1 | -168.07 | 71.6 | 18.74 |
Net Income Growth | - | - | - | - | 282.09% | 2927.14% |
Shares Outstanding (Basic) | 74 | 72 | 72 | 71 | 63 | 60 |
Shares Outstanding (Diluted) | 74 | 72 | 72 | 71 | 64 | 60 |
Shares Change | 1.58% | - | 1.89% | 11.87% | 5.12% | 0.23% |
EPS (Basic) | -0.35 | -0.54 | -3.08 | -2.36 | 1.13 | 0.31 |
EPS (Diluted) | -0.35 | -0.54 | -3.08 | -2.36 | 1.13 | 0.31 |
EPS Growth | - | - | - | - | 267.48% | 3103.13% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -92.1 | -160.28 | -305.39 | -246.28 | -115.21 | -121.35 |
Free Cash Flow Per Share | -1.25 | -2.21 | -4.21 | -3.46 | -1.81 | -2.01 |
Dividend Per Share | - | - | - | - | 0.098 | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 28.22% | 32.66% | 30.37% | 30.27% | 32.46% | 28.19% |
Operating Margin | -18.04% | -11.88% | -27.11% | -20.67% | -8.00% | -7.35% |
Profit Margin | -3.58% | -5.57% | -43.10% | -42.43% | 17.09% | 4.81% |
Free Cash Flow Margin | -12.82% | -22.63% | -59.00% | -62.17% | -27.50% | -31.12% |
EBITDA | -60.47 | -20.73 | -85.84 | -49.01 | -5.41 | 0.81 |
EBITDA Margin | -8.42% | -2.93% | -16.59% | -12.37% | -1.29% | 0.21% |
D&A For EBITDA | 69.05 | 63.43 | 54.45 | 32.89 | 28.1 | 29.47 |
EBIT | -129.52 | -84.16 | -140.29 | -81.9 | -33.52 | -28.66 |
EBIT Margin | -18.04% | -11.88% | -27.11% | -20.67% | -8.00% | -7.35% |
Effective Tax Rate | - | - | - | - | 0.92% | - |